From launching the first NAT assays for blood screening, Roche has consistently remained in the forefront in keeping the blood supply safe through active surveillance of emerging infections and through rapid development of screening solutions.
Roche NAT instruments, assays and reagents have been developed using the gold standard real-time Polymerase Chain Reaction (PCR ) technology, a very sensitive and high-performing technology that detects DNA and RNA molecules of infectious agents such as HIV/HCV/HBV at an early stage of an infection. Easily integrated into pre- and post-analytic solutions they enable donor screening facilities to fully automate operations, boost throughput and achieve quicker turnaround times - leading to greater overall workflow efficiency.
Roche’s state-of-the-art NAT assays provide comprehensive genotype coverage and excellent sensitivity. Together with analyzers that provide efficient workflows, deliver fast results and minimize loss of donated blood products, Roche’s leading molecular diagnostic solutions deliver predictable operational outcomes for laboratories and help reduce the risk of disease transmission and adverse health effects in patients.